Reports Q3 revenue $72,000, consensus $110,000. “We are focused on driving execution of our potentially best-in-class anti-IGF-1R therapies to reach meaningful clinical readouts in our intravenous and subcutaneous TED franchise,” said Steve Mahoney, President and CEO of Viridian Therapeutics. “We recently reiterated our expectations for our timelines and unveiled our novel anti-FcRn portfolio for autoimmune diseases with our first investigational new drug (IND) submission for this program planned by year end 2024. Finally, our recent closing of a private placement for approximately $185 million enables our allocation of capital to the most value-creating results for patients and shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRDN:
- VRDN Upcoming Earnings Report: What to Expect?
- Viridian Therapeutics price target lowered to $35 from $44 at RBC Capital
- Viridian Therapeutics price target lowered to $37 from $46 at Wedbush
- Viridian in device customization, supply pact with Ypsomed for TED drug delivery
- Short Report: Bears step back from Lucid following tw0-month slide